Can HALP (Hemoglobin, albumin, lymphocyte, and platelet) score distinguish malignant and benign causes of extrahepatic cholestasis in patients with extrahepatic bile duct obstruction?

Basit Öğe Kaydı
dc.contributor.authorDusunceli, Ibrahimhalil
dc.contributor.authorSargin, Zeynep Gok
dc.contributor.authorCelik, Umut
dc.contributor.authorSargin, Fatih
dc.date.accessioned2025-01-21T16:27:04Z
dc.date.available2025-01-21T16:27:04Z
dc.date.issued2024
dc.departmentKırıkkale Üniversitesi
dc.description.abstractOBJECTIVE: Cholestatic diseases are common and classified as benign or malignant based on their etiology. HALP is a unique nutritional immune marker that combines indicators of nutritional status, including hemoglobin and albumin, with immune function markers like lymphocyte and platelet counts. We investigated the HALP score’s ability to differentiate between benign and malignant causes in extrahepatic cholestasis patients. METHODS: This research was designed as cross-sectional and retrospective. Between 1 January 2020–1 January 2022, patients diagnosed with extrahepatic cholestasis were included. The diagnoses were confirmed using non-invasive imaging meth-ods, ERCP (endoscopic retrograde cholangiopancreatography), and tissue biopsy results. Based on the type of extrahepatic biliary obstruction, either benign or malignant, the patients were divided into two groups. The HALP score was calculated by multiplying the patient’s albumin (g/L), hemoglobin (g/L), and lymphocyte count (/L) and dividing by the platelet count (/L). RESULTS: In 121 of 216 patients, extrahepatic cholestasis was caused by benign factors, mostly choledocholithiasis, while malignant causes, predominantly pancreatic head cancer, were responsible for extrahepatic cholestasis in 95 patients. The malignant cholestasis group had significantly higher bilirubin levels (p<0.001), lower hemoglobin levels (p=0.005), lower albumin levels (p<0.001), higher lymphocyte counts (p<0.001), and higher platelet levels (p=0.001) compared to the benign cholesta-sis group. There was no considerable difference in the HALP score between the two groups, as indicated by a p-value of 0.741. CONCLUSION: The HALP score could not distinguish between benign and malignant causes of extrahepatic cholestasis. © 2024, Kare Publishing. All rights reserved.
dc.identifier.doi10.14744/NCI.2024.23169
dc.identifier.endpage559
dc.identifier.issn2148-4902
dc.identifier.issue6
dc.identifier.scopus2-s2.0-85211339586
dc.identifier.scopusqualityQ4
dc.identifier.startpage555
dc.identifier.urihttps://doi.org/10.14744/NCI.2024.23169
dc.identifier.urihttps://hdl.handle.net/20.500.12587/23245
dc.identifier.volume11
dc.indekslendigikaynakScopus
dc.language.isoen
dc.publisherKare Publishing
dc.relation.ispartofNorthern Clinics of Istanbul
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_20241229
dc.subjectAlbumin; extrahepatic cholestasis; HALP score; hemoglobin; lymphocytes; platelets
dc.titleCan HALP (Hemoglobin, albumin, lymphocyte, and platelet) score distinguish malignant and benign causes of extrahepatic cholestasis in patients with extrahepatic bile duct obstruction?
dc.title.alternativeHALP (Hemoglobin, albümin, lenfosit ve trombosit) skoru, ekstrahepatik safra kanalı obstruksiyonu olan hastalarda ekstrahepatik kolestazın malign ve benign nedenlerini ayırt edebilir mi?
dc.typeArticle

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu